Core Insights - 20/20 BioLabs, Inc. is an early market leader in AI-powered laboratory-based blood tests for early detection and prevention of cancers and chronic diseases [3][5] - The company will host a virtual investor webinar on February 26, 2026, to discuss its recent Nasdaq listing and product offerings [4][5] - The company offers two main products: OneTest™ for Cancer™, a multi-cancer early detection blood test, and OneTest for Longevity™, which measures inflammatory biomarkers [5][6] Company Overview - 20/20 BioLabs was listed on Nasdaq under the ticker symbol "AIDX" on February 19, 2026 [5] - The company operates a CAP-accredited and CLIA-licensed laboratory in Gaithersburg, MD, where tests are conducted [6] - The company also runs a Clinical Laboratory Innovation Accelerator (CLIAx) to support overseas diagnostics start-ups [7] Upcoming Initiatives - The OneTest for Longevity™ is expected to launch before the end of February 2026 [4] - The virtual investor webinar will include a question-and-answer session, allowing investors to engage directly with the company's leadership [4][5]

Core Viewpoint - 20/20 BioLabs, Inc. has launched its Class A ordinary shares on the Nasdaq Capital Market under the ticker symbol "AIDX," aiming to scale growth through AI-powered blood tests for cancer and chronic disease detection [1][6]. Financing and Growth Strategy - The company has entered a contingent financing agreement that could provide up to $40 million, with the first $5 million expected to close today [2]. - The CEO emphasized that the Nasdaq listing is a significant milestone that positions the company for substantial growth through both organic means and mergers and acquisitions [6][7]. Product Offerings - 20/20 BioLabs offers OneTest™ for Cancer, an AI-powered multi-cancer early detection blood test that analyzes tumor-associated protein biomarkers, allowing for earlier detection of multiple cancers at a lower price point than competing tests [4][11]. - The upcoming OneTest for Longevity™, expected to launch by the end of February, will track inflammatory biomarkers associated with chronic diseases, enabling consumers to make lifestyle changes to reduce disease risk [5][11]. Technological Innovation - The company's diagnostics leverage AI models built with real-world data, enhancing accuracy and clinical usefulness, and allowing for convenient home access through new blood collection devices [3][11]. - The OneTest for Cancer may be the first multi-cancer early detection test that can be self-collected at home, which is a significant advancement in the field [4]. Regulatory Environment - Recent legislation passed by Congress aims to facilitate Medicare reimbursement for multi-cancer early detection tests by 2028, which could positively impact the company's market potential [4]. Investor Relations - 20/20 BioLabs has launched an Investor Relations section on its website, providing various resources for investors, including press releases, current share prices, and SEC filings [8].